Cargando…
Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
BACKGROUND AND OBJECTIVES: Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Accordingly, the drug–drug interaction (DDI) potential of darolutamide was investigated in both nonclinical and clinical stu...
Autores principales: | Zurth, Christian, Koskinen, Mikko, Fricke, Robert, Prien, Olaf, Korjamo, Timo, Graudenz, Kristina, Denner, Karsten, Bairlein, Michaela, von Bühler, Clemens-Jeremias, Wilkinson, Gary, Gieschen, Hille |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828636/ https://www.ncbi.nlm.nih.gov/pubmed/31571146 http://dx.doi.org/10.1007/s13318-019-00577-5 |
Ejemplares similares
-
Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
por: Shore, Neal, et al.
Publicado: (2019) -
Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment
por: Zurth, Christian, et al.
Publicado: (2021) -
Darolutamide for prostate cancer
Publicado: (2020) -
In vivo Metabolism of Nifurtimox and the Drug-Drug Interaction Potential Including its Major Metabolites
por: Schulz, Simone I., et al.
Publicado: (2023) -
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial
por: Williams, Steven C. R., et al.
Publicado: (2023)